Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim
- Citation:
- Support Care Cancer vol 24 (7) 3085-3093
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 5
- Parents:
- 2136
- Children:
- None
- Program:
- CCP
- Primary Committee:
- Symptom Inter
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Grants:
- U10CA037447, U10 CA031946, U10 CA037447, U10 CA180821, UG1 CA189823
- Corr. Author:
- Authors:
- J. Moukharskaya D.M. Abrams T. Ashikaga F. Khan J. Schwartz K. Wilson C. Verschraegen T. Openshaw J. Valentine J. Eneman P. Unger S. Ades
- Networks:
- LAPS-MA036, LAPS-OH007, ME040, NEWMEXICO, VT004, WESTERN
- Study
- NCT01311336
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- pegfilgrastim, bone pain, prophylaxis, antihistamine, loratadine, taxane